160 related articles for article (PubMed ID: 36332548)
1. Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2.
Di Micco S; Rahimova R; Sala M; Scala MC; Vivenzio G; Musella S; Andrei G; Remans K; Mammri L; Snoeck R; Bifulco G; Di Matteo F; Vestuto V; Campiglia P; Márquez JA; Fasano A
Eur J Med Chem; 2022 Dec; 244():114857. PubMed ID: 36332548
[TBL] [Abstract][Full Text] [Related]
2. Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors.
Ghosh AK; Shahabi D; Yadav M; Kovela S; Anson BJ; Lendy EK; Bonham C; Sirohi D; Brito-Sierra CA; Hattori SI; Kuhn R; Mitsuya H; Mesecar AD
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641337
[TBL] [Abstract][Full Text] [Related]
3. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
Huff S; Kummetha IR; Tiwari SK; Huante MB; Clark AE; Wang S; Bray W; Smith D; Carlin AF; Endsley M; Rana TM
J Med Chem; 2022 Feb; 65(4):2866-2879. PubMed ID: 34570513
[TBL] [Abstract][Full Text] [Related]
5. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
[TBL] [Abstract][Full Text] [Related]
6. Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation.
Di Micco S; Musella S; Sala M; Scala MC; Andrei G; Snoeck R; Bifulco G; Campiglia P; Fasano A
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502335
[TBL] [Abstract][Full Text] [Related]
7. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
8. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
[TBL] [Abstract][Full Text] [Related]
9. Repurposing an Antiviral Drug against SARS-CoV-2 Main Protease.
Sarkar A; Mandal K
Angew Chem Int Ed Engl; 2021 Oct; 60(44):23492-23494. PubMed ID: 34545983
[TBL] [Abstract][Full Text] [Related]
10. Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication.
Vuong W; Khan MB; Fischer C; Arutyunova E; Lamer T; Shields J; Saffran HA; McKay RT; van Belkum MJ; Joyce MA; Young HS; Tyrrell DL; Vederas JC; Lemieux MJ
Nat Commun; 2020 Aug; 11(1):4282. PubMed ID: 32855413
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulants as Potential SARS-CoV-2 M
Abo Elmaaty A; Eldehna WM; Khattab M; Kutkat O; Alnajjar R; El-Taweel AN; Al-Rashood ST; Abourehab MAS; Binjubair FA; Saleh MA; Belal A; Al-Karmalawy AA
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293094
[TBL] [Abstract][Full Text] [Related]
12. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
13. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
Martorana A; Gentile C; Lauria A
Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
[TBL] [Abstract][Full Text] [Related]
14. Synthetic flavonoids as potential antiviral agents against SARS-CoV-2 main protease.
Batool F; Mughal EU; Zia K; Sadiq A; Naeem N; Javid A; Ul-Haq Z; Saeed M
J Biomol Struct Dyn; 2022 May; 40(8):3777-3788. PubMed ID: 33251983
[TBL] [Abstract][Full Text] [Related]
15. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M
Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR
Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682
[TBL] [Abstract][Full Text] [Related]
16. Easy access to α-ketoamides as SARS-CoV-2 and MERS M
Pelliccia S; Cerchia C; Esposito F; Cannalire R; Corona A; Costanzi E; Kuzikov M; Gribbon P; Zaliani A; Brindisi M; Storici P; Tramontano E; Summa V
Eur J Med Chem; 2022 Dec; 244():114853. PubMed ID: 36332546
[TBL] [Abstract][Full Text] [Related]
17. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease.
Akaji K; Konno H
Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349
[TBL] [Abstract][Full Text] [Related]
18. Molecular interactions and inhibition of the SARS-CoV-2 main protease by a thiadiazolidinone derivative.
Andrzejczyk J; Jovic K; Brown LM; Pascetta VG; Varga K; Vashisth H
Proteins; 2022 Nov; 90(11):1896-1907. PubMed ID: 35567429
[TBL] [Abstract][Full Text] [Related]
19. Theaflavin 3-gallate inhibits the main protease (M
Chauhan M; Bhardwaj VK; Kumar A; Kumar V; Kumar P; Enayathullah MG; Thomas J; George J; Kumar BK; Purohit R; Kumar A; Kumar S
Sci Rep; 2022 Jul; 12(1):13146. PubMed ID: 35908093
[TBL] [Abstract][Full Text] [Related]
20. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
Awoonor-Williams E
Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
